Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Reports
|
Ambient Air Pollution and All-Cause and Cause-Specific Mortality in an Analysis of Asian Cohortsinfo:eu-repo/semantics/OpenAccess ;ISSN: 1041-5505 ;EISSN: 2688-6855Full text available |
|
2 |
Material Type: Reports
|
Brucella, a bacterium with multiple ways of causing infectionBaylor University Medical Center Proceedings, 2021, Vol.34 (1), p.99-101Copyright © 2020 Baylor University Medical Center 2020 ;ISSN: 0899-8280 ;EISSN: 1525-3252 ;DOI: 10.1080/08998280.2020.1805674Full text available |
|
3 |
Material Type: Reports
|
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodiesmAbs, 2023, Vol.15 (1)2023 Crown Copyright. Published with license by Taylor & Francis Group, LLC. 2023 ;ISSN: 1942-0862 ;EISSN: 1942-0870 ;DOI: 10.1080/19420862.2023.2239405Full text available |
|
4 |
Material Type: Reports
|
Case report of a criminal dismemberment in Northeast BrazilForensic Sciences Research: Special Issue on The Reality of the Dead in Brazil; Guest Editors Eugénia Cunha, Bridget Algee-Hewitt and Melina Calmon, 2022, Vol.7 (4), p.637-6422022 The Author(s). Published by Taylor & Francis Group on behalf of the Academy of Forensic Science. 2022 ;ISSN: 2096-1790 ;EISSN: 2471-1411 ;DOI: 10.1080/20961790.2022.2055828Full text available |
|
5 |
Material Type: Reports
|
The "microwave oven" practice in BrazilForensic Sciences Research: Special Issue on The Reality of the Dead in Brazil; Guest Editors Eugénia Cunha, Bridget Algee-Hewitt and Melina Calmon, 2022, Vol.7 (4), p.628-6322023 The Author(s). Published by Taylor & Francis Group on behalf of the Academy of Forensic Science. 2023 ;ISSN: 2096-1790 ;EISSN: 2471-1411 ;DOI: 10.1080/20961790.2022.2067727Full text available |
|
6 |
Material Type: Reports
|
SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical caseHuman Vaccines & Immunotherapeutics, 2022, Vol.18 (6)2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2022.2101334Full text available |
|
7 |
Material Type: Reports
|
Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategiesmAbs, 2023, Vol.15 (1)2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 ;ISSN: 1942-0862 ;EISSN: 1942-0870 ;DOI: 10.1080/19420862.2023.2292305Full text available |
|
8 |
Material Type: Reports
|
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasismAbs, 2023, Vol.15 (1)2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 ;ISSN: 1942-0862 ;EISSN: 1942-0870 ;DOI: 10.1080/19420862.2023.2209920Full text available |
|
9 |
Material Type: Reports
|
Validation of the new EPIC DNA methylation microarray (900K EPIC v2) for high-throughput profiling of the human DNA methylomeEpigenetics, 2023, Vol.18 (1)2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023 ;ISSN: 1559-2294 ;EISSN: 1559-2308 ;DOI: 10.1080/15592294.2023.2185742Full text available |
|
10 |
Material Type: Reports
|
Talking about recommended age or fewer doses: what motivates HPV vaccination timeliness?Human Vaccines & Immunotherapeutics, 2021, Vol.17 (9), p.3077-30802021 Taylor & Francis Group, LLC 2021 ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2021.1912550Full text available |
|
11 |
Material Type: Reports
|
Human papillomavirus prevalence, genomic diversity and related risk factors in HIV-positive women from a countryside city in the state of Rio de JaneiroHuman Vaccines & Immunotherapeutics, 2021, Vol.17 (3), p.838-8442020 The Author(s). Published with license by Taylor & Francis Group, LLC. 2020 ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2020.1799666Full text available |
|
12 |
Material Type: Reports
|
The human antibody sequence space and structural design of the V, J regions, and CDRH3 with RosettamAbs, 2022, Vol.14 (1)2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 ;ISSN: 1942-0862 ;EISSN: 1942-0870 ;DOI: 10.1080/19420862.2022.2068212Full text available |
|
13 |
Material Type: Reports
|
The human gut serves as a reservoir of hypervirulent Klebsiella pneumoniaeGut Microbes, 2022, Vol.14 (1)2022 The Author(s). Published with license by Taylor & Francis Group, LLC. 2022 ;ISSN: 1949-0976 ;EISSN: 1949-0984 ;DOI: 10.1080/19490976.2022.2114739Full text available |
|
14 |
Material Type: Reports
|
Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-upHuman Vaccines & Immunotherapeutics, 2021, Vol.17 (4), p.943-9492020 Merck & Co. Inc. Published with license by Taylor and Francis Group, LLC 2020 ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2020.1839292Full text available |
|
15 |
Material Type: Reports
|
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibodyOncoImmunology, 2023, Vol.12 (1)2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 ;EISSN: 2162-402X ;DOI: 10.1080/2162402X.2023.2255041Full text available |
|
16 |
Material Type: Reports
|
Therapeutic effects and mechanism of human amnion-derived mesenchymal stem cells on hypercoagulability in a uremic calciphylaxis patientRenal Failure, 2023, Vol.45 (1)2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2023 ;ISSN: 0886-022X ;EISSN: 1525-6049 ;DOI: 10.1080/0886022X.2023.2218483Full text available |
|
17 |
Material Type: Reports
|
Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopesmAbs, 2019, Vol.11 (8), p.1415-14272019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 ;ISSN: 1942-0862 ;EISSN: 1942-0870 ;DOI: 10.1080/19420862.2019.1654304Full text available |
|
18 |
Material Type: Reports
|
Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case reportHuman Vaccines & Immunotherapeutics, 2022, Vol.18 (1), p.1-42021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2021.1953349Full text available |
|
19 |
Material Type: Reports
|
Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trialsHuman Vaccines & Immunotherapeutics, 2020, Vol.16 (3), p.590-5942019 Taylor & Francis Group, LLC 2019 ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2019.1669413Full text available |
|
20 |
Material Type: Reports
|
Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case reportHuman Vaccines & Immunotherapeutics, 2023, Vol.19 (2)2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023 ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2023.2252252Full text available |